NASDAQ:NMTR 9 Meters Biopharma (NMTR) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsInsider TradesSEC FilingsTrendsBuy This Stock About 9 Meters Biopharma Stock (NASDAQ:NMTR) 30 days 90 days 365 days Advanced Chart Get 9 Meters Biopharma alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume906 shsAverage Volume315,915 shsMarket Capitalization$1.04 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. Its lead product candidate is Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 3 clinical trial to treat short bowel syndrome. The company is developing NM-136, a humanized monoclonal antibody for the treatment of obesity and obesity-related disorders; NM-102, a small molecule peptide to prevent antigens from trafficking into systemic circulation; and NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease. Its partnered product is Larazotide, an 8-amino acid peptide, which is in Phase 2 clinical trial for treatment of multi-system inflammatory syndrome. The company has licensing agreements with Amunix, MHS Care Innovation LLC, Alba Therapeutics Corporation, and EBRIS. 9 Meters Biopharma, Inc. is headquartered in Raleigh, North Carolina. On July 17, 2023, 9 Meters Biopharma, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Eastern District of North Carolina.Read More… Receive NMTR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for 9 Meters Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address NMTR Stock News HeadlinesEnergy firms likely to miss smart meter deadline, warns Which?December 14, 2023 | bbc.comDeal reached to sell some assets of bankrupt Raleigh firmNovember 8, 2023 | bizjournals.comWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week, President Trump promised to buy a Tesla to help support Musk in the face of a boycott against his company. But according to one research group, with connections to the Pentagon and the U.S. government, Elon's preparing to strike back in a much bigger way in the days ahead.May 4, 2025 | Altimetry (Ad)9 Meters Biopharma, Inc. (NMTRQ)November 7, 2023 | finance.yahoo.com9 Meters Biopharma Inc (NMTRQ)October 17, 2023 | investing.com9 Meters Biopharma (OTC: NMTR.Q)August 16, 2023 | fool.comRaleigh firm joins worrying trend of bankruptcies for drugmakersJuly 18, 2023 | bizjournals.comDrug developer 9 Meters Biopharma files for bankruptcy protectionJuly 18, 2023 | reuters.comSee More Headlines NMTR Stock Analysis - Frequently Asked Questions How were 9 Meters Biopharma's earnings last quarter? 9 Meters Biopharma, Inc. (NASDAQ:NMTR) released its quarterly earnings results on Monday, November, 15th. The company reported ($1.00) earnings per share for the quarter, missing the consensus estimate of ($0.74) by $0.26. When did 9 Meters Biopharma's stock split? 9 Meters Biopharma's stock reverse split on the morning of Tuesday, October 18th 2022. The 1-20 reverse split was announced on Tuesday, October 18th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, October 18th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of 9 Meters Biopharma? Shares of NMTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of 9 Meters Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that 9 Meters Biopharma investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), SNDL (SNDL), NIO (NIO), Advanced Micro Devices (AMD) and Alibaba Group (BABA). Company Calendar Last Earnings11/15/2021Today5/04/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:NMTR CIK1551986 Webwww.9meters.com Phone(919) 275-1933FaxN/AEmployees20Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($3.46) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-43,770,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-584.97% Return on Assets-159.45% Debt Debt-to-Equity RatioN/A Current Ratio0.59 Quick Ratio0.59 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.19 per share Price / BookN/AMiscellaneous Outstanding Shares14,336,000Free Float13,992,000Market Cap$1.04 million OptionableNo Data Beta1.36 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report This page (NASDAQ:NMTR) was last updated on 5/4/2025 by MarketBeat.com Staff From Our PartnersWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTrump to solve American wealth loss?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredWill May start the next "Great Depression?"You probably haven't heard about this yet... But this could be the biggest wealth building opportunity of t...Behind the Markets | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 9 Meters Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share 9 Meters Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.